^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

    Published date:
    06/21/2022
    Excerpt:
    Patients with intermediate- or poor-risk disease should be offered combination treatment with two immune checkpoint inhibitors (ICIs; ie, ipilimumab and nivolumab)…
    DOI:
    10.1200/JCO.22.00868
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    First-line treatment for advanced ccRCC...Ipilimumab–nivolumab continues to be recommended as first-line treatment for IMDC intermediate- and poor-risk disease…
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/03/2021
    Excerpt:
    …the NCCN Kidney Cancer Panel considers nivolumab and ipilimumab a category 2A preferred subsequent therapy option for patients with clear cell RCC.